Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Strategic Pivot | Editas Medicine shifts focus to in vivo gene editing, restructuring operations and extending cash runway amid market challenges and pipeline changes |
Financial Outlook | Analyst price targets range from $1 to $8, reflecting uncertainty. Cash reserves extended to Q2 2027, but profitability remains distant |
Competitive Edge | Explore Editas' potential in liver and HSC editing, leveraging strong IP portfolio for partnerships in a less crowded market segment |
Future Catalysts | Delve into Editas' long-term prospects in emerging in vivo gene editing field, balancing extended runway against pipeline uncertainties |
Metrics to compare | EDIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEDITPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.5x | −2.5x | −0.7x | |
PEG Ratio | −0.12 | −0.10 | 0.00 | |
Price/Book | 0.6x | 1.1x | 2.6x | |
Price / LTM Sales | 1.8x | 16.9x | 3.1x | |
Upside (Analyst Target) | 153.6% | 677.8% | 47.6% | |
Fair Value Upside | Unlock | 31.1% | 7.7% | Unlock |